139 related articles for article (PubMed ID: 27616199)
21. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model.
Clark PA; Al-Ahmad AJ; Qian T; Zhang RR; Wilson HK; Weichert JP; Palecek SP; Kuo JS; Shusta EV
Mol Pharm; 2016 Sep; 13(9):3341-9. PubMed ID: 27421304
[TBL] [Abstract][Full Text] [Related]
22. Pleural metastatic disease from glioblastoma multiforme.
Gotway MB; Conomos PJ; Bremner RM
J Thorac Imaging; 2011 May; 26(2):W54-8. PubMed ID: 20634762
[TBL] [Abstract][Full Text] [Related]
23. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report.
Zhu X; McDowell MM; Newman WC; Mason GE; Greene S; Tamber MS
J Neurosurg Pediatr; 2017 Feb; 19(2):249-253. PubMed ID: 27858578
[TBL] [Abstract][Full Text] [Related]
24. Diagnosed recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET.
García JR; Baquero M; Bassa P; Soler M; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):398-9. PubMed ID: 26092078
[No Abstract] [Full Text] [Related]
25. [How useful are microsurgical operations in the treatment concept for glioblastoma multiforme].
Stummer W; Tonn JC
MMW Fortschr Med; 2004 Apr; 146(14):28-30. PubMed ID: 15344748
[No Abstract] [Full Text] [Related]
26. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme.
Fadul CE; Wen PY; Kim L; Olson JJ
J Neurooncol; 2008 Sep; 89(3):339-57. PubMed ID: 18712284
[No Abstract] [Full Text] [Related]
27. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
28. Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Thakur A; Joshi N; Shanmugam T; Banerjee R
Cancer Lett; 2013 Jul; 334(2):274-83. PubMed ID: 22935677
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo.
Erdlenbruch B; Jendrossek V; Marx M; Hunold A; Eibl H; Lakomek M
Anticancer Res; 1998; 18(4A):2551-7. PubMed ID: 9703909
[TBL] [Abstract][Full Text] [Related]
30. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
[TBL] [Abstract][Full Text] [Related]
31. Does the choice of antiepileptic drug have an impact on the survival of glioblastoma multiforme?
Guthrie G; Eljamel S
Br J Neurosurg; 2013 Apr; 27(2):270. PubMed ID: 23472621
[No Abstract] [Full Text] [Related]
32. New developments in targeted molecular therapies for glioblastoma.
Wen PY
Expert Rev Anticancer Ther; 2009 Jan; 9(1):7-10. PubMed ID: 19105702
[No Abstract] [Full Text] [Related]
33. The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model.
Awde AR; Boisgard R; Thézé B; Dubois A; Zheng J; Dollé F; Jacobs AH; Tavitian B; Winkeler A
J Nucl Med; 2013 Dec; 54(12):2125-31. PubMed ID: 24212976
[TBL] [Abstract][Full Text] [Related]
34. Setting the stage: local delivery of cytoreductive agents for the treatment of glioblastoma.
Kalkanis SN
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii1-ii2. PubMed ID: 25746088
[No Abstract] [Full Text] [Related]
35. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Lukas RV; Goldenberg F; Nicholas MK
J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885
[TBL] [Abstract][Full Text] [Related]
37. Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Engel JB; Schönhals T; Häusler S; Krockenberger M; Schmidt M; Horn E; Köster F; Dietl J; Wischhusen J; Honig A
Arch Gynecol Obstet; 2011 Mar; 283(3):603-10. PubMed ID: 20405296
[TBL] [Abstract][Full Text] [Related]
38. Methods of resistance to epidermal growth factor receptor inhibition in glioblastoma multiforme.
Komotar RJ; Starke RM; Connolly ES; Sisti MB
Neurosurgery; 2012 Feb; 70(2):N13-4. PubMed ID: 22251981
[No Abstract] [Full Text] [Related]
39. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Ma DJ; Galanis E; Anderson SK; Schiff D; Kaufmann TJ; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Flynn PJ; Ligon KL; Buckner JC; Sarkaria JN
Neuro Oncol; 2015 Sep; 17(9):1261-9. PubMed ID: 25526733
[TBL] [Abstract][Full Text] [Related]
40. Current status of intratumoral therapy for glioblastoma.
Mehta AI; Linninger A; Lesniak MS; Engelhard HH
J Neurooncol; 2015 Oct; 125(1):1-7. PubMed ID: 26233248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
